All In MedTech

Device Trial Radar · NCT04591938

FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Safety and Efficacy of the FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo Coronary Artery Disease: the ENCORE-I Study

Last checked: Nov 20, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 1, 2019

Primary completion

Jun 1, 2021

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Joost DaemenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Horizon 2020 - European Commission; REVA Medical, Inc.
First posted
Oct 19, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multicentre, non-randomized, investigator-initiated study aiming to assess the safety and efficacy of the Fantom Encore sirolimus-eluting bioresorbable scaffold (BRS).

Conditions

  • Percutaneous Coronary Intervention
  • Myocardial Revascularization
  • Tomography, Optical Coherence

Interventions

  • Fantom Encore Bioresorbable scaffold implantationDevice

    Fantom Encore Bioresorbable scaffold implantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device-Oriented Composite Endpoint (DOCE)Time frame: 12 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Ziekenhuis Oost-Limburg

    Genk, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium · Not yet recruiting

  • Erasmus Medical Center

    Rotterdam, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.